all 3 news articles
Drug maker Wyeth has received US government approval to replace its successful antidepressant Effexor XR (venlafaxine hydrochloride), which is facing patent ...
By STEPHANIE SAUL Faced with the looming loss of patent protection for its top-selling drug, the antidepressant Effexor XR, Wyeth received federal approval ...
The new drug is slated to replace the company's top-selling Effexor drug when a cheaper generic version will become available as early as this summer. ...
Effexor XR, Wyeth's extended-release depression drug, last year pulled in $3.8 billion — 17 percent of its total revenue. Cheaper generic competition is ...
Desvenlafaxine is a metabolite and follow-on compound of the company's venlafaxine (Effexor), an antidepressant with patent protection expiring this year. ...
By STEPHANIE SAUL Faced with the looming loss of patent protection for its top-selling drug, the antidepressant Effexor XR, Wyeth on Friday received federal ...
After several setbacks, Wyeth won FDA approval for antidepressant Pristiq, the son of Effexor, now the company’s bestseller. Patents covering Effexor begin ...
A study in the Public Library of Science reported that antidepressants – drugs like Prozac, Paxil and Effexor – don't work much better than a placebo. ...
PRISTIQ delivers the major active metabolite of EFFEXOR XR(R) (venlafaxine HCl) in its active state without going through the CYP2D6 metabolic pathway. ...